European drug regulators advised women who take birth control pills and Eli Lilly's Mounjaro to take extra steps to ensure their contraception remains effective while on the diabetes and weight-loss drug.
The European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, said it now advises patients on birth control pills to add a backup method of contraception for four weeks after starting Mounjaro, and for four weeks after each dose increase.
The CHMP said it alternatively advises Mounjaro patients to switch to a non-oral method of contraception.
The CHMP said its guidance would be disseminated to healthcare professionals by Eli Lilly following a decision by the European Commission.
Women who can become pregnant and are using Mounjaro are recommended to use contraception.
The CHMP--which is responsible for assessing the quality, safety and efficacy of medicines in the EU, and issuing recommendations to the European Commission--said there is limited information available on the effect of tirzepatide on the efficacy of oral contraceptives in women with obesity, overweight or type 2 diabetes mellitus.
Comments